| Title of Invention | VECTOR FOR GENE THERAPY |
|---|---|
| Abstract | The present invention provides a retroviral vector containing a transcription unit comprising a transcription regulatory sequence and a gene encoding a polypeptide having single-stranded RNA-specific endoribonuclease activity which is placed so that its expression can be controlled by the regulatory sequence, wherein the unit is placed so that the direction of the transcription of mRNA from the unit is opposite to the direction of transcription of the RNA genome of the retroviral vector. By using the vector constructed as described above, viral supernatant showing high gene transfer efficiency can be prepared. The retroviral vector of the present invention is useful for the treatment and/or prevention of cancers and virus infections. |
| Full Text | The present invention provides a retroviral vector containing a transcription unit comprising a transcription regulatory sequence and a gene encoding a polypeptide having single-stranded RNA-specific endoribonuclease activity which is placed so that its expression can be controlled by the regulatory sequence, wherein the unit is placed so that the direction of the transcription of mRNA from the unit is opposite to the direction of transcription of the RNA genome of the retroviral vector. By using the vector constructed as described above, viral supernatant showing high gene transfer efficiency can be prepared. The retroviral vector of the present invention is useful for the treatment and/or prevention of cancers and virus infections. Claims 1. A retroviral vector which comprises a transcription unit comprising a transcription regulatory sequence and a gene encoding a polypeptide having single-stranded RNA-specific endoribonuclease activity which is placed so that its expression can be controlled by the regulatory sequence, wherein the unit is placed so that the direction of transcription of mRNA from the unit is opposite to the direction of transcription of RNA genome of the retroviral vector. 2. The retroviral vector according to claim 1, wherein the transcription regulatory sequence is a sequence for controlling the transcription of a gene expressed specifically in cancer cells or virus-infected cells. 3. The retroviral vector according to claim 1, wherein the transcription regulatory sequence is such a sequence that the transcription is induced by a trans-acting factor of a cancer cell or virus origin. 4. The retroviral vector according to claim 3, wherein the transcription regulatory sequence is such a sequence that the transcription is induced by a trans-acting factor of an immunodeficiency virus. 5. The retroviral vector according to claim 4, which comprises such a transcription regulatory sequence that the transcription is induced by Tat protein and/or Rev protein. 6. The retroviral vector according to claim 4, wherein a gene encoding a polypeptide having single-stranded RNA-specific endoribonuclease activity is placed downstream of the LTR of an immunodeficiency virus. 7. The retroviral vector according to claim 1, wherein the transcription regulatory sequence is such a sequence that the transcription is induced by a trans-acting factor artificially supplied into cells. 8. The retroviral vector according to any one of claims 1 to 7, wherein the polypeptide having single-stranded RNA-specific endoribonuclease activity is MazF protein. 9. A method for treating or preventing a disease, which comprises introducing the retroviral vector according to any one of claims 1 to 8 into cells. 10. The method according to claim 9, wherein the disease is a cancer or a virus infection. 11. The method according to claim 9, wherein the disease is an immunodeficiency virus infection. 12. A therapeutic or preventive agent of a disease, which comprises the retroviral vector according to any one of claims 1 to 8 as an effective component. 13. The therapeutic or preventive agent according to claim 12 for treating or preventing cancer or virus infection. 14. The therapeutic or preventive agent according to claim 13 for treating or preventing an immunodeficiency virus infection. |
|---|
| Patent Number | 270740 | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indian Patent Application Number | 6702/DELNP/2009 | ||||||||||||||||||||
| PG Journal Number | 03/2016 | ||||||||||||||||||||
| Publication Date | 15-Jan-2016 | ||||||||||||||||||||
| Grant Date | 14-Jan-2016 | ||||||||||||||||||||
| Date of Filing | 20-Oct-2009 | ||||||||||||||||||||
| Name of Patentee | See attached documents | ||||||||||||||||||||
| Applicant Address | See attached documents | ||||||||||||||||||||
Inventors:
|
|||||||||||||||||||||
| PCT International Classification Number | C12N 15/09 | ||||||||||||||||||||
| PCT International Application Number | PCT/JP2008/057414 | ||||||||||||||||||||
| PCT International Filing date | 2008-04-16 | ||||||||||||||||||||
PCT Conventions:
|
|||||||||||||||||||||